

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	1	
Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	Filone.
Group Number:	NPI:	State Lic ID:
Address:	Address:	Otate Lie ID.
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. Select the regimen being requested.		
☐ Stelara 90 mg SubQ every 8 weeks		
☐ Stelara 90 mg SubQ every 12 weeks		
☐ Stelara 45 mg SubQ every 12 weeks		
☐ IV Induction: 260 mg		
☐ IV Induction: 390 mg		
☐ IV Induction: 520 mg		
☐ Other		
Q2. What diagnosis is this drug being prescribed for (select ALL that apply)?		
☐ Plaque psoriasis ☐ Psoriatic arthritis	☐ Crohn's Disease [Other
Q3. Provide ICD code(s) for diagnosis.		
Q4. Please indicate location of administration.		
☐ Home		
☐ Physician office (drug from office stock - buy and bill)		
☐ Physician office (MEMBER to obtain drug from PHARI	MACY with a prescription)	



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
☐ Other		
Q5. What is the prescriber's specialty?		
☐ Dermatologist ☐ Rheumatologist	☐ Gastroenterology ☐ Other	
Q6. Select ALL of the following that apply to the patient:		
 ☐ Moderate to severe PLAQUE PSORIASIS affecting GREATER THAN 5% of body surface area (BSA) ☐ Moderate to severe PLAQUE PSORIASIS affecting CRUCIAL BODY AREAS such as hands, feet, face, or genitals ☐ PSORIATIC ARTHRITIS with documented SPINAL INVOLVEMENT (psoriatic spondylitis) 		
☐ None of the above		
Q7. Has the patient failed at least TWO TOPICAL treatment analogues, Vitamin D analogue/corticosteroid combination Yes No N/A - Patient does not have plaque psoriasis	•	
Q8. Has the patient failed, or does the patient have a control Yes No N/A - Patient does not have plaque psoriasis	aindication to phototherapy (UVB or PUVA)?	
Q9. Select ALL of the following that apply to this patient:		
☐ For psoriasis, failed AT LEAST ONE of the following sulfasalazine, tacrolimus	: methotrexate, cyclosporine, acitretin, leflunomide,	
☐ For psoriasis, contraindication to methotrexate, cycle☐ For psoriatic arthritis, failed methotrexate	osporine, acitretin, leflunomide, sulfasalazine, or tacrolimus	
For psoriatic arthritis, contraindication to methotrexa		
For psoriatic arthritis, failed AT LEAST ONE of the for tacrolimus	ollowing: sulfasalazine, leflunomide, cyclosporine, acitretin,	
 ☐ For psoriatic arthritis, contraindication to sulfasalazin ☐ For Crohn's Disease, failure of or contraindication to corticosteroid, or an immunosuppressive 	ne, leflunomide, cyclosporine, acitretin, tacrolimus an anti-inflammatory drug (e.g. mesalamine, sulfasalazine),	
Q10. Is the patient a NEW START to Stelara?		



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
☐ Yes ☐ No		
Q11. Select the agents the patient has failed Enbrel Humira Other (please specify) None		
Q12. Has the patient failed Cosentyx?		
Q13. What is the patient's weight? Less than or equal to 55 kg (121 lbs) 55 to 85 kg (121 to 187 lbs) 86 to 100 kg (189 to 220 lbs) Greater than 100 kg (220 lbs)		
Q14. For continuation of Stelara for Crohn's disease, is there documentation of clinical response from the IV initiation dose? [Please submit clinical documentation]		
Q15. Additional Comments		
Prescriber Signature	Date	
□ Expedited/Urgent - By checking this box and signing abor	ve, I certify that applying the standard review timeframe may	

seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Stelara (Ustekinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
Patient Name:	Supervising Physician:

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document